About Pluslife
Founded in 2017, we leverage next-generation genetic technologies to create innovative, accurate, and cost-effective molecular diagnostic solutions, aiming to decentralize infectious disease testing and enhance global health security.
Established by the first cohort of nationally recognized high-level talents, we embrace a philosophy of diversity in talent. Our team includes professors, postdoctoral researchers, and strategic development experts from the in vitro diagnostics industry, protein engineering, and investment fields such as CFA.
Operating from over 10,000 square meters of facilities, we focus on advancing molecular POCT technologies. Using our proprietary RHAM technology, we have developed diagnostic solutions for infectious diseases, respiratory and reproductive infections, and animal pathogens. With over 170 patents filed, 50 granted, and 120+ overseas certifications, our reach spans multiple countries worldwide.
Corporate Positioning
Revolutionizing and Decentralizing Infectious Disease Diagnosis with Innovative, Rapid, Accurate, and Affordable Molecular POCT Solutions
-
2018
Establish an independent intellectual property core raw material enzyme screening platform
-
2019
Obtained the Guangzhou Industry Leading Talent Agglomeration Project · Entrepreneurship Leading Team
-
2020
▶ Participated in the key scientific research project of COVID-19 prevention and control in Guangzhou
▶ RHAM technology completed research and development -
2021
Completed Series A financing of 100 million yuan
COVID-19 test kit and test platform MiniDock are launchedISO 13485 certification obtained
-
2022
▶ Product entering mass production
▶ Recommended projects for rapid nucleic acid testing by the Ministry of Science and Technology, with priority evaluation
▶ Parallel development of multiple pipelines
▶ Series A+financing of 50 million yuan -
2023
▶ Awarded the title of "Guangdong Province 2022 Specialized, Refined, Special, and New Small and Medium sized Enterprises"
▶ Successfully developed over 30 types of testing products
▶ Register and advertise in multiple countries and regions
▶ Collaborate with well-known international NGOs such as FIND and BMGF -
2024
● Publication of clinical validation data in scientific journals
● Pluslife's RHAM patented technology accuracy validated by authoritative international academic institutions
● Invited to attend the 3rd National Tuberculosis Innovation Forum and the 4th International Forum on Tuberculosis R&D Cooperation
Milestone
Technology Platform
Independently developed patented technology RHAM
——
Independently developed patented technology RHAM
——
RHAM technology effectively overcomes the shortcomings of non-specific amplification (LAMP), insufficient sensitivity (RPA), long reaction time (NASBA), insufficient compatibility and patent limitation (CRISPR) of similar isothermal amplification technologies, and truly achieves the landing of high sensitivity and high specificity nucleic acid POCT rapid detection.
Autonomous raw material enzyme
——
Autonomous raw material enzyme
——
All product raw materials are self-produced by enzymes, with a new generation of enzyme directed evolution platform and protein expression platform, which can achieve large-scale production of protein raw materials at the level of millions per month.
Autonomous POCT process&fully automated production line
——
Autonomous POCT process&fully automated production line
——
With independent patented technology, the entire production line is automated, and the testing reagent kit can reach a monthly production capacity of millions of people.
Contact Us
Tel: +86-20-31703986
E-mail: market@pluslife.com (Business Enquiry)
service@pluslife.com (After-Sales & Technical Support)
Add: 3F-Block E, Runhui Science & Technology Park, No.18 Shenzhou RD, Huangpu District, Guangzhou, Guangdong, China
Copyright © Established